Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 51,555

Document Document Title
WO/2016/202310A1
A sulphonated pentasaccharide compound having anti-Xa factor activity, and a preparation method and use for said compound. The compound is a derivative of a pentasaccharide compound having an anticoagulation effect, and has significant a...  
WO/2016/205062A1
Methods for treating thrombosis and cardiovascular disease with inhibitors that bind to Factor Xa are provided herein.  
WO/2016/205595A1
The methods and compositions described herein relate to the treatment of bowel inflammation, e.g., IBD or a thrombosis, ischemia, and/or pulmonary embolism associated with IBD by administering ADAMTS13 to a subject.  
WO/2016/205570A1
The present invention provides expression vectors for use in an inducible coexpression system, capable of controlled induction of expression of each gene product.  
WO/2016/202462A1
The invention relates to a dialysis solution or substitution solution which contains bicarbonate ions and calcium and/or magnesium ions, the dialysis solution or the substitution solution further containing an organic phosphoric acid ester.  
WO/2016/203314A1
The invention relates to novel chemical entities that act as thromboxane (TX) A2 receptor, or T prostanoid receptor (TP), antagonists and to their use in the treatment of human diseases in which thromboxane (TX) A and of all other agents...  
WO/2016/205482A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or d...  
WO/2016/204256A1
The present invention provides a high-performance platelet production enhancer that includes one or multiple aryl hydrocarbon receptor (AhR) antagonists and one or multiple Rho-associated coiled-coil forming kinase (ROCK) inhibitors.  
WO/2016/202854A1
The invention relates to an in vitro method of diagnosis of hereditary xerocytosis in a subject, comprising genotyping the KCNN4 gene encoding the Gardos channel in said subject. The invention also relates to an inhibitor of the KCNN4 pr...  
WO/2016/204696A1
The present invention provides isolated peptides, variants and fragments thereof that are capable of binding with a high level of specificity to thrombin and inhibiting its activity. There is also provided uses of such peptides in method...  
WO/2016/197980A1
The present invention relates to the technical field of pharmaceutical chemistry, especially to Baicalin crystal form A, and preparation method and application thereof. The crystal form shows characteristic peaks at X-ray powder diffract...  
WO/2016/196281A1
The present invention relates to treatments and therapies for anemia conditions and diseases of the blood, and more particular is a therapy for the acute and chronic treatment of sickle cell diseases and thalassemia by administration of ...  
WO/2016/191879A1
The present description relates to in vitro methods for culturing hematopoietic stem cells (HSCs) under mild hyperthermia conditions (e.g., between 38°C and 40°C) in the presence of a pyrimidoindole derivative agonist of hematopoietic ...  
WO/2016/194855A1
The present invention addresses the problem of providing: a novel peptide having a high medicinal effect and high efficacy; and a medicine and an external preparation, particularly a prophylactic or therapeutic agent for dermatitis, rhin...  
WO/2016/194778A1
[Problem] To provide a vasorelaxant from food that has few side effects and is safe for hypertension patients and healthy persons said to have prehypertension. The problem is also to provide foods and beverages including this composition...  
WO/2016/191700A1
The invention provides pharmaceutical compositions and dosage forms of fluorocarbon nanoemulsions that are useful for treating sickle cell disease and related diseases and conditions, as well as methods of preparation and use thereof.  
WO/2016/188907A1
The invention relates to a polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment of a blood coagulation disorder, wherein the polypeptide carries a half-life extending moiety and is administered in molar...  
WO/2016/190750A1
Improving the antioxidant capacity in an animal by increasing the level of glutathione in the blood or tissue of the animal comprising providing a composition containing beta- casein to the animal for consumption, where the beta-casein c...  
WO/2016/191698A1
This invention is directed to, inter alia, compositions comprised of pentosan polysulfate sodium (PPS) components and methods for making such compositions and using the same for the treatment of sickle cell disease (SCD). The disclosed c...  
WO/2016/186140A1
The present invention addresses the problem of providing a novel membrane permeability-improving agent which can be applied to polymeric drugs. More specifically, the present invention addresses the problem of providing: a drug carrier w...  
WO/2016/183785A1
A traditional Chinese medicine for treating an allergic purpura is prepared from the following raw materials (in parts by weight): lithospermum erythrorhizon roots (10 parts), bupleurum roots (10 parts), red peony roots (10 parts), mouta...  
WO/2016/186071A1
Provided is an oligopeptide having preventive and therapeutic effects on infarction diseases. The oligopeptide includes the DE loop sequence of the RANKL protein, and has an activity to inhibit cells from secreting proinflammatory cytoki...  
WO/2016/187353A1
Methods and compositions for improved clinical outcomes for trauma patients receiving whole blood transfusion. Methods and compositions for improved clinical outcomes for blood transfusions for cancer patients are also provided.  
WO/2016/186994A1
Described herein are methods, assays, and compositions relating to the treatment of thrombosis, preeclampsia, cancer, and intestinal inflammation, e.g., by administering ADAMTS13 to a subject in need of treatment.  
WO/2016/180784A1
Potential side effects of unintentional activation of platelets by phosphorothioated oligonucleotides are minimised in various ways, including a combination therapy, wherein PS-ONs are combined, in one composition, a kit-of-parts, and/or...  
WO/2016/181894A1
The present invention provides a compound which has an excellent TLR4 signaling inhibitory effect and is useful as a prophylactic or therapeutic agent for diseases such as autoimmune diseases and/or inflammatory diseases, chemotherapy-in...  
WO/2016/180205A1
Disclosed are a novel crystal form of dextro borneol ferulate, a preparation method therefor, a pharmaceutical composition comprising same and application of the novel crystal form. A dextro borneol ferulate crystal form provided in the ...  
WO/2016/183280A1
Provided herein are methods of treating beta-thalassemia by subcutaneous administration of about 0.8 mg/kg of an ActRII signaling inhibitor. Also provided herein are methods of adjusting the dose of the ActRII signaling inhibitor adminis...  
WO/2016/183009A3
This invention relates to compounds, compositions, and methods useful for reducing AT3 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.  
WO/2016/181135A1
The use of acetazolamide and methazolamide for the control and monitoring of thrombosis and clotting Acetazolamide and methazolamide, are used for the treatment, prevention, control and monitoring of thrombosis and clotting.  
WO/2016/177870A1
The invention relates to a composition strongly enriched with anti-A and/or anti-B polyclonal immunoglobulins, comprising polyclonal human immunoglobulins, characterised in that at least 80 wt.-% of the polyclonal human immunoglobulins p...  
WO/2016/177013A1
Disclosed is the use of a curcumin and a pharmaceutically acceptable salt thereof in the preparation of drugs for antitumor associated syndrome. Curcumin can improve anemia while inhibiting tumors.  
WO/2016/173948A1
The present application relates to novel substituted indazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular fo...  
WO/2016/169296A1
A drug inhibiting thrombosis, the active ingredient of the drug consisting of triflusal and ticagrelor having certain proportions, the mass ratio of the triflusal and the ticagrelor being 20 : 1 – 1 : 6. Experimental results show that ...  
WO/2016/168949A1
A drug inhibiting thrombosis, the active ingredients of the drug being triflusal and ticagrelor, the mass ratio of the triflusal and the ticagrelor being (100–650) : (30–150), preferably (1–20) : 1, more preferably (3–6) : 1, and...  
WO/2016/172479A1
Described herein are methods and compositions for treatment of diabetes and/or obesity. Bitter oligopeptide molecules formulated for enteric delivery modulate signals involving receptors facing the lumen of the gastrointestinal tract, sa...  
WO/2016/171202A1
Using commercially available plasma from patients with coagulation factor XI disorders, the present inventors have found that multispecific antigen binding molecules that substitute for FVIII function have a plasma procoagulant effect. I...  
WO/2016/167276A1
The purpose of the present invention is to develop a technique for amplifying hematopoietic stem cells. Hematopoietic stem cells can be amplified by using at least one HDGF substance.  
WO/2016/161988A3
Provided are a pharmaceutical composition containing spherical clopidogrel bisulphate crystalline form I, and a preparation method for the pharmaceutical composition. The powder properties of the pharmaceutical composition are beneficial...  
WO/2016/161990A3
Provided are a coating formulation and coating process applicable to both clopidogrel bisulphate and allisartan isoproxil. The formulation has a better isolation effect compared to the prior art, enables a preparation to also remain stab...  
WO/2016/161991A3
Provided is a clopidogrel bisulphate solid preparation, prepared via a melt granulation process. The drug content in the resulting granules is high and the uniformity is good.  
WO/2016/161570A1
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein CH, R1, R1a, R1b, R2, R3, and the subscripts m1, m2, p, q, and t are as set...  
WO/2016/164501A1
In certain aspects, the disclosure provides soluble single-arm heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family or an extracellular domain of a type ...  
WO/2016/162369A1
The present invention relates to a von Willebrand factor composition for preventing and/or treating haemorrhages and/or bleeding in patients under mechanical circulatory support.  
WO/2016/159204A1
The present invention pertains to a therapeutic composition for disseminated intravascular coagulation syndrome, disseminated intravascular coagulation syndrome associated with a decrease in antithrombin, or thrombophilia based on heredi...  
WO/2016/155357A1
The present invention relates to a compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heterooxy, a preparation method thereof and a pharmaceutical use thereof. In particular, the compound has the following formula (I), wh...  
WO/2016/158756A1
Provided are: an intradermal formulation for regenerative medicine for performing a treatment to safely, simply, and reliably induce and mature the regeneration or rebirth of lymph vessels, blood vessels, or granulation in conditions suc...  
WO/2016/155653A1
Disclosed are two axially chiral isomers and pharmaceutically available salts thereof, preparation methods therefor, and pharmaceutical uses of the two axially chiral isomers or pharmaceutical compositions thereof.  
WO/2016/154766A1
The invention relates to a pediculicide formulation based on Eucalyptus globulus essential oil, which is effective on P. humanus capitis, provides ovicidal activity, an effect on the adhesion of the P. humanus egg, a short estimated time...  
WO/2016/155359A1
The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently H; R3 is selected from H, a C1-C7straight-chain, and a branched or cyclic alkyl; ...  

Matches 551 - 600 out of 51,555